DISPERSION OF STREPTOCOCCUS MUTANS BIOFILMS BY A NOVEL SMALL MOLECULE
通过新型小分子分散变形链球菌生物膜
基本信息
- 批准号:8652185
- 负责人:
- 金额:$ 4.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-09 至 2015-09-08
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinity ChromatographyAnti-Bacterial AgentsAntibiotic ResistanceAntibiotic TherapyAntibioticsArchitectureBacteriaBiological AssayBiological FactorsCarbohydratesChemicalsChildCollaborationsCommunicable DiseasesComplexDNADataDental EnamelDental cariesDevelopmentDietDietary SugarsDiseaseDrug TargetingExcisionExhibitsExtracellular ProteinFluoridesGenesGenetic TranscriptionGerm-FreeGlucansGlucosyltransferasesGoalsHA coatingImageIn VitroIncidenceKnock-outLactic acidLaser Scanning Confocal MicroscopyLibrariesLipidsMaintenanceMarinesMarketingMass Spectrum AnalysisMetabolismMethodsMicrobial BiofilmsModelingMouthwashOral cavityOrganismPathogenesisPathway interactionsPharmaceutical PreparationsPopulationPoriferaPreventionProductionPropertyRattusResistanceSalivaScienceSerotypingStreptavidinStreptococcusStreptococcus gordoniiStreptococcus mutansStructureSucroseTestingTherapeutic AgentsTooth structureToothpasteantimicrobialbasecariogenic bacteriademineralizationeffective therapyglucosyltransferase Bglucosyltransferase Din vivokillingsmicroorganismmutantnoveloral commensalpathogenic bacteriapreventpublic health relevancescreeningsmall moleculesmall molecule librariestherapeutic targettooth surfacetranscriptome sequencing
项目摘要
DESCRIPTION (provided by applicant): Dental caries is a costly disease characterized by the demineralization of the enamel, otherwise known as tooth decay. Despite advances in science, dental caries is the most common infectious disease worldwide and is increasing in incidence among young children. The etiologic causative agent of dental caries is Streptococcus mutans. Not only can S. mutans form biofilms readily on the tooth surface, but this bacterium rapidly produces lactic acid from dietary sugars. Dental caries cannot be easily treated with conventional antibiotics as cariogenic bacteria form tenacious biofilms, which are resistant to antibiotics. Current marketed therapies lack sensitivity; they are not species-specific and kill pathogenic species as well as commensal species, which are protective against the formation of pathogenic biofilms. In order to develop a therapeutic agent that is species specific for S. mutans, we constructed a diverse library of small molecules based on the structural motifs of bromoageliferin, a marine sponge product with antibiofilm and antibacterial properties. In a previous study, we utilized the library in a biofilm formation inhibition assay to identify potent small molecules that inhibit S. mutans biofilm formation specifically. Currently, we are redirecting our approach to focus on dispersing established S. mutans biofilms. By screening our library of small molecules with a biofilm dispersion assay, we identified 3F1 as a novel small molecule that selectively disperses S. mutans biofilms. While 3F1 dispersed approximately 50% of S. mutans biofilm, it did not disperse biofilms formed by commensal species Streptococcus sanguinis or Streptococcus gordonii. Confocal laser scanning microscopy images revealed that 3F1 altered the architecture of the biofilm by affecting the exopolymeric matrix, made evident through the reduced amount of exopolysaccharides. Glucosyltransferases (Gtfs) secreted by S. mutans are largely responsible for forming the exopolysaccharides which make up a large proportion of the exopolymeric matrix. The activity of 3F1 was not negated by the absence of the primary Gtf, GtfB, leading us to hypothesize that our small molecule induces the dispersal of S. mutans biofilms by interacting with a potentially unique and unknown mechanism related to the development and production of the exopolymeric matrix, which is necessary for biofilm maturation, structure, or maintenance. The identification of a novel target implicated in biofilm formation in S. mutans could potentially become a therapeutic target for the prevention or treatment of dental caries, while maintaining the commensal populations.
描述(由申请人提供):龋齿是一种昂贵的疾病,其特征是釉质脱矿,也称为蛀牙。尽管科学进步,龋齿是世界上最常见的传染病,并且在幼儿中的发病率正在增加。龋病的病原体是变形链球菌。不仅可以S。变形杆菌很容易在牙齿表面形成生物膜,但这种细菌从食物中的糖迅速产生乳酸。龋齿不容易用常规抗生素治疗,因为致龋细菌形成对抗生素具有抗性的坚韧生物膜。目前市售的疗法缺乏敏感性;它们不是物种特异性的,并且杀死病原性物种以及病原性物种,其保护免于形成病原性生物膜。为了开发对S.为了鉴定变异株,我们构建了一个基于溴ageliferin结构基序的小分子多样性文库,溴ageliferin是一种具有抗菌膜和抗菌特性的海绵产品。在以前的研究中,我们利用生物膜形成抑制试验中的文库来鉴定抑制S.变形菌生物膜的形成。目前,我们正在重新调整我们的方法,集中精力分散既定的S。变形杆菌生物膜通过用生物膜分散试验筛选我们的小分子文库,我们鉴定了3F 1作为一种选择性分散S.变形杆菌生物膜而3F 1分散了约50%的S.变形链球菌生物膜,它不分散由嗜酸菌种血链球菌或戈登链球菌形成的生物膜。共聚焦激光扫描显微镜图像显示,3F 1通过影响胞外聚合物基质改变了生物膜的结构,通过减少胞外多糖的量而变得明显。葡萄糖基转移酶(Gtfs)是由S.变形杆菌主要负责形成构成大部分外聚合物基质的外多糖。3F 1的活性并不因缺乏主要的Gtf、GtfB而被否定,这使我们假设我们的小分子诱导了S的扩散。通过与与外聚合基质的发育和产生相关的潜在独特和未知的机制相互作用,该外聚合基质是生物膜成熟、结构或维持所必需的。一个新的目标涉及生物膜形成的S。变形杆菌有可能成为预防或治疗龋齿的治疗靶点,同时保持牙菌群。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sandra Stephanie Garcia其他文献
Sandra Stephanie Garcia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sandra Stephanie Garcia', 18)}}的其他基金
DISPERSION OF STREPTOCOCCUS MUTANS BIOFILMS BY A NOVEL SMALL MOLECULE
通过新型小分子分散变形链球菌生物膜
- 批准号:
8734901 - 财政年份:2013
- 资助金额:
$ 4.3万 - 项目类别:
DISPERSION OF STREPTOCOCCUS MUTANS BIOFILMS BY A NOVEL SMALL MOLECULE
通过新型小分子分散变形链球菌生物膜
- 批准号:
8997999 - 财政年份:2013
- 资助金额:
$ 4.3万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 4.3万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 4.3万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 4.3万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 4.3万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 4.3万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 4.3万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 4.3万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 4.3万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 4.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 4.3万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




